Antares pharma inc.
The FDA has approved the oral drug estosterone undecanoate (Tlando; Antares Pharma, Inc) for testosterone replacement therapy (TRT) for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult patients. “The FDA approval of Tlando brings to market an oral formulation of testosterone that we believe …
Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery ...Antares Pharma, Inc. (Nasdaq - ATRS) Under the terms of the agreement, Antares will be acquired by Halozyme Therapeutics, Inc. (“Halozyme”) (Nasdaq - HALO). Antares stockholders will receive ...SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. …About us. About Antares Antares Pharma is a specialty pharmaceutical company that combines drug development expertise with proprietary delivery technology to deliver safe and effective...
Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.As pet owners, we want to keep our furry friends safe and secure. Invisible Fence Inc. has been providing pet owners with innovative solutions to keep their pets out of harm’s way for over 40 years. With their advanced technology, Invisible...Abstract. Medi-Ject Corporation (now Antares Pharma, Inc.) has been providing delivery devices for the needle-free administration of insulin for over 25 years. This study was one of the final steps in the development and premarket evaluation of Medi-Ject's newest needle-free system, the Medi-Jector Vision. This study was conducted to evaluate ...
Antares Pharma's (NASDAQ:ATRS) stock up by 8.0% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...Jun 24, 2014 · Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.
Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Antares Pharma, Inc. (Amex:AIS) has elected Leonard S. Jacob, M.D., Ph.D. to the Company ' s Board of Directors.. Dr. Leonard Jacob joins Antares with over 29 years of pharmaceutical industry experience including having founded InKine Pharmaceutical Company Inc. in 1997 and served as Chairman and CEO from its …SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. …“At one minute following 11:59 p.m., Eastern Time, on May 23, 2022, the Offer expired. Equiniti Trust Company, the depository and paying agent for the Offer, advised Purchaser that, as of the expiration of the Offer, a total of 139,371,158 Shares were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 81.56% of …
Antares Pharma, Inc. announced the appointment of Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will oversee the...
Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...
Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Mar 3, 2022 · EWING, NJ, March 3, 2022 – Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted ... Antares Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation SA Transcripts Thu, Nov. 05, 2020 Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call TranscriptDelaware . 1-32302 . 41-1350192 (State or other jurisdiction. of incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...Jan 11, 2022 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...
Halozyme Inc. is an Equal Employment Opportunity (EEO) employer. It is the policy of the Company to provide equal employment opportunities to all qualified applicants without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, protected veteran or disabled status, or genetic information.Antares Pharma, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 41.56 million compared to USD 42.08 million a year ago. Net loss was USD 2.32 million compared to net income of USD 3.79 million a year ago. Basic loss per share from continuing operations …Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic …Antares Pharma, Inc. Website. Get a D&B Hoovers Free Trial. Overview Company Description: Antares Pharma understands antagonism towards needles. The company develops needle-free systems for administering injectable drugs. Its Medi-Jector Vision system, for instance, injects a thin, high-pressure stream of liquid, eliminating the need …Antares Pharma, Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. The Company …About Antares Pharma . Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Antares Pharma, Inc. announced the appointment of Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will oversee the...
Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million.
Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ...SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...Revenue in 2021: $0.18 B ... According to Antares Pharma's latest financial reports the company's current revenue (TTM) is $0.18 B. In 2021 the company made a ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ...Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto ...
Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...
Antares Pharma Inc (NASDAQ:ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ:HALO) for $5.60 per share in cash, valuing ...
Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …Assignee(s): Antares Pharma, Inc. A jet injector that includes a prefilled syringe. The syringe includes a fluid chamber that contains a medicament. The syringe also has an injection-assisting needle, and a plunger is movable within the fluid chamber. A housing is configured for allowing insertion of the needle to a penetration depth. An …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...Jan 11, 2022 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate …Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Pfizer will assume full cost and responsibility for all clinical development, manufacturing, …Plaintiff–Appellant Antares Pharma, Inc. (“Antares”) appeals from a decision of the United States District Court for the District of Delaware denying Antares' motion for preliminary injunction. Antares seeks to enjoin alleged infringement of claims 31, 34, 35, and 37 of a reissue patent, RE44, 846 (“the '846 patent”).Home :: Antares Pharma. As of May 24, 2022 Halozyme completed its acquisition of Antares Pharma, Inc., creating a leading drug delivery business with broadly licensable …Mar 3, 2022 · EWING, NJ, March 3, 2022 – Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted ... Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...About Antares. Antares Pharma is a specialty pharmaceutical company that combines drug development expertise with proprietary delivery technology to deliver safe and effective medicines. With a goal of improving dosing, reducing side effects, and improving patient compliance and outcomes, our pursuit of innovative therapies strives to ...
Antares Pharma Inc (NASDAQ:ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ:HALO) for $5.60 per share in cash, valuing ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …May 6, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ... Instagram:https://instagram. biggest gambling cities in usstock price of tencent holdingsamazon crypto coinbest mortgage lenders in ny Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Oct 18, 2021 · Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States. TLANDO is an oral testosterone product for testosterone replacement therapy ("TRT") in ... arm ipo robinhoodcancer insurance providers Oct 18, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. Dec 20, 2011 · Tiberend Strategic Advisors, Inc. Jason Rando. (212) 827-0020. [email protected]. Share. Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. how to invest in instacart Exhibit 99.1 . Halozyme Completes Antares Pharma Acquisition . SAN DIEGO, May 24, 2022 — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the successful completion of its acquisition of Antares Pharma, Inc. (“Antares”).. The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at …Apr 13, 2022 · Halozyme Therapeutics Inc. agreed to a nearly $1 billion deal to buy specialty pharmaceutical company Antares Pharma Inc. in a move that will deepen its focus on drug delivery. Halozyme on ... Jan 25, 2022 ... Serghei Lungu v. Antares Pharma Inc, No. 21-1624 (3d Cir. 2022) case opinion from the US Court of Appeals for the Third Circuit.